



## Content highlights

### Release date

Throughout 2023

Updated quarterly to reflect Clarivate's expert analysis of the latest major-market events

### Geography

Global

### Secondary research

Clinical trial registries, regulatory databases, company pipelines, annual reports, news articles, company press releases, and presentations.

### Drug classes covered

Oncology MABs, TNF- $\alpha$  inhibitors, interleukin, insulins, ESAs, HGHs, recombinant blood factors, G-CSFs, interferons, ophthalmology MABs, and more.

### Content highlights

Interactive database providing information on the biosimilar pipeline, split by metrics such as company, molecule, phase, and country of development.

Graphical summaries of key metrics including which drug classes are most popular for biosimilar development.

Expected launch timings in the major markets (United States, Europe, and Japan).

# Biosimilars

## Spotlight on Emerging Biosimilars

### Market outlook

Of all the 700+ biosimilars globally tracked by Clarivate, almost one-third are in preclinical development. The current size of the global biosimilars development pipeline highlights the potential growth of the biosimilars market in the years to come. Drug classes frequently targeted by biosimilar developers include monoclonal antibodies used in oncology, and TNF- $\alpha$  inhibitors and interleukins used in autoimmune indications. However, as developers enter emerging therapeutic spaces such as ophthalmology, CNS and niche and rare diseases, Clarivate continues to keep up with new trends to provide you with the latest competitive insights in biosimilar development.

### Questions answered

- How many biosimilar candidates are currently undergoing phase I or III clinical development in a particular region?
- Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
- Which are the top 10 biosimilars developers by number of clinical stage candidates?
- When is the expected launch date for late-stage pipeline candidates in the seven major markets?
- What is the level of competition expected for a brand, globally and by region/country?
- Key companies covered include: Amgen, Allergan, Biocon, Celltrion, Dr. Reddy's, Fresenius Kabi, Gedeon Richter, Intas, Merck & Co, Pfizer, Samsung Bioepis, Sandoz, Shanghai Henlius Biotech, Teva, Viatrix (Mylan).

### Product description

Clarivate's *Biosimilars | Emerging Biosimilars* module provides a detailed view of evolving biosimilars landscape in the major markets, so you can optimize your market access strategy and determine how to best position your brand to specific stakeholders. We track over 700 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. Updates are made quarterly.

### Solution enhancement

*Biosimilars | Emerging Biosimilars* features frequent updates to provide timely insights and analyses as meaningful news and events unfold.

Learn more about Clarivate's full suite of biosimilars solutions.

[DRG.support@clarivate.com](mailto:DRG.support@clarivate.com) | [clarivate.com](https://clarivate.com)